Navigation Links
ThromboGenics N.V.: Business Update
Date:11/6/2008

howed that microplasmin-treated patients had a statistically significant improvement in the level of damage to the blood brain barrier compared to placebo-treated patients, measured using the marker of matrix metalloproteinase (MMP). MMP activation plays a crucial role in the pathogenesis of brain edema and hemorrhagic transformation after ischemic stroke.

It remains ThromboGenics' intention that it will only move forward with the development of microplasmin for the treatment of stroke in cooperation with a partner. This view is based on both the risks and cost associated with the development of new stroke therapies, and the Company's desire to invest in its other attractive pipeline product candidates, including microplasmin in the treatment of back of the eye diseases.

Staphylokinase (THR-100)

ThromboGenics partner for the clinical development and commercialization of THR-100, Bharat Biotech, continues to work with the Indian authorities to gain the necessary approvals to begin a Phase III trial with this novel variant of Recombinant Staphylokinase. The initial trial will evaluate THR-100 for the treatment of acute myocardial infarction (AMI), or heart attack. Given the commercial strengths of Bharat in this market and the clinical advantages of THR-100, it is hoped that this novel product will quickly become the market leader for the thrombolytic treatment of heart attacks in India.

TB-403 - Working with Roche on this Potential Breakthrough Cancer Treatment

ThromboGenics, in conjunction with its partner BioInvent, has made good progress in transferring this novel anti-cancer agent to Roche following the strategic alliance signed in June 2008.

Following the successful completion of the initial Phase I study, the parties have begun a Phase Ib trial with TB-403 in end-stage cancer patients. This study, which will recruit approximately 24 patients, is designed to provide both safety data on TB-403 when used in cancer patients
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThromboGenics Announces Half Year Results 2008
2. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
3. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
4. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
5. ThromboGenics N.V. - Business Update
6. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
7. ThromboGenics Announces 2007 Full Year Results
8. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
9. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
10. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
11. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... May 27, 2015 Research and Markets( ... PharmaBiotech,s new report "Neuroprotection - Drugs, Markets ... This report describes the role of neuroprotection in ... the nervous system as well as in chronic ... the underlying mechanisms of damage to neural tissues ...
(Date:5/28/2015)... 28, 2015 Celsion Corporation (the "Company") (NASDAQ: ... commitments from two institutional healthcare investors to purchase an ... stock in an at-the-market registered direct offering and a ... The Company entered into a definitive purchase ... agreed to sell an aggregate of 3,000,000 shares of ...
(Date:5/28/2015)... DryLet, LLC a biotechnology company providing ... animal waste reduction, bioremediation, wastewater treatment, aquaculture and ... plants and restaurant kitchen settings, announced today it ... 3-5 in Des Moines, Iowa. , ManureMagicâ„¢ was ... Journal article because of its industry-leading qualities and ...
(Date:5/28/2015)... 2015  PDS Biotechnology Corp. announces preliminary data ... HPV-16, has generated strong T-cell responses in pre-cervical ... is treated by surgical removal of lesions however, ... alternative. Results show that it primes and activates ... and kill precancerous and cancerous cells that display ...
Breaking Biology Technology:Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 3Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3DryLet to Showcase Patented ManureMagicâ„¢ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2
... Gizmox, the developer of Visual WebGui Web ... the Business Mobility Market. Visual WebGui,s Instant CloudMove migration, ... Web or Cloud, has now been extended to make ... mapping and configuration tool.  IdeoMobile, in partnership with Gizmox, ...
... Patent 7,824,612 ("Body Fluid Analyzer and System including Same and ... of their patented Technology to create a new class of ... analyzers. These tablets wirelessly inform a body fluid ... the drug company so that the analyzer can provide alerts ...
... AVAX Technologies, Inc. (Pink Sheets: AVXT ... filed a Form 10 with the Securities and Exchange ... AVAX will once again become a publicly reporting company. ... stock trade on the Over-the-Counter Bulletin Board.  The Company,s ...
Cached Biology Technology:Gizmox Enters the Business Mobile Application Market - Visual WebGui Based Solutions Deployed in Major Financial and Medical Institutions 2Gizmox Enters the Business Mobile Application Market - Visual WebGui Based Solutions Deployed in Major Financial and Medical Institutions 3AVAX Technologies, Inc. Files Form 10 With SEC 2
(Date:4/27/2015)... Apr. 27, 2015 Profile Solutions, Inc. (OTC: ... security systems is pleased to announce that Dr ... consultant and member of its scientific advisory board. ... as a thought leader in technology-enhanced learning models. He ... and has published studies and books focused on online ...
(Date:4/20/2015)... -- The announcement comes as demand for ... (GRM), Ireland,s foremost records management company, ... up an impressive track record of clients within the first ... records management sector in Dubai . As ... and employ a further eight staff members at its Irish ...
(Date:4/14/2015)... OXFORD, Conn. , April 14, 2015 ... "Company"), a biometric authentication company focused on the growing ... has been nominated for the 2015 New York Design ... The Design100, New York City Design Awards are ... are based on over 2,500 ratings from the marketplace, ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... Current research suggests that a common oral bacterium may exacerbate ... "Unique Lipids from a Common Human Bacterium Represent a New ... the December 2009 issue of The American Journal of ... immune system attacks the brain and spinal cord, affects nearly ...
... 16, 2009 -- A USDOE and USDA study concluded ... and cropland pasture could be converted from current uses ... from which biomass could be harvested for use as ... grass monoculture from which substantial quantities of biomass are ...
... University of Southern California biomedical engineer and cardiologist ... tool to help clinicians distinguish cardiac emergencies requiring ... and lifestyle change. Angiograms, images made by ... offer an inside view of the interior surface ...
Cached Biology News:Factors from common human bacteria may trigger multiple sclerosis 2Switchgrass produces biomass efficiently 2Stable plaque or heart attack plaque? USC researcher builds new sensor to tell which is which 2
Recalibration of HL-2000-CAL products...
Human HVEM/TNFRSF14 Allophycocyanin MAb (Clone 94801)...
Enodgenous alkaline phosphotase inhibitor. Levamisole solution is supplied in concentrated form (20x). The final concentration of levamisole in the substrate solution will be 1 mM....
X-gal,1g...
Biology Products: